刘媛;赵林;
LIU Yuan;ZHAO Lin;Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

• 1:中国医学科学院北京协和医院肿瘤内科

摘要(Abstract)：

近日，美国国立综合癌症网络发布了2022年最新版胃癌临床实践指南。该版指南不仅细化了对腹腔转移性肿瘤的评估、术后放疗的适应证以及三药联合化疗的推荐，更为重要的是首次推荐高通量测序技术用于微卫星不稳定(microsatellite instability, MSI)/错配修复(mismatch repair, MMR)状态的检测，并推荐将MSI/MMR状态检测扩大至全人群。同时，在后线治疗中新增了数种基于分子分型的新药推荐，指明了未来胃癌精准治疗的方向。本文将对新版胃癌临床实践指南，特别是其更新部分进行解读，以期为临床实践提供指导和帮助。
Recently, National Comprehensive Cancer Network(NCCN) released the latest version of clinical practice guidelines for gastric cancer. In this version, evaluation of peritoneal metastasis using laparoscopy with cytology has been refined. Postoperative chemoradiation is recommended as an alternative option for patients who have received less than a D2 lymph node dissection. The use of three cytotoxic drugs in a regimen should be reserved for medically fit patients with excellent performance status and easy access to frequent toxicity evaluation. More importantly, next generation sequencing(NGS) is recommended for the first time for the detection of microsatellite instability/mismatch repair(MSI/MMR)status. In addition, the recommendation for the detection of MSI/MMR status is extended to all newly diagnosed cases. Several recently developed targeted drugs and immuno-oncology therapy are included in the recommendation for sequential treatment. Precise treatment strategy based on biomarkers will inevitably become the future direction for gastric cancer. This article aims to interpret the updates to provide reference for clinical practice.

关键词(KeyWords)： 胃癌;NCCN指南;指南更新
gastric cancer;NCCN guideline;guideline update

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 刘媛;赵林;
LIU Yuan;ZHAO Lin;Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

参考文献(References)：

• [1] Ajani JA,D'Amico TA,Bentrem DJ,et al.Gastric Cancer,Version 2.2022,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2022,20:167- 192.
• [2] International Agency for Research on Cancer.GLOBOCAN 2020:stomach cancer fact sheet[EB/OL].(2020- 12)[2022- 05- 01].https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf.
• [3] Morgan E,Arnold M,Camargo MC,et al.The current and future incidence and mortality of gastric cancer in 185 countries,2020- 40:A population-based modelling study[J].EClinicalMedicine,2022,47:101404.
• [4] Sitarz R,Skierucha M,Mielko J,et al.Gastric cancer:epidemiology,prevention,classification,and treatment[J].Cancer Manag Res,2018,10:239- 248.
• [5] Ma J,Shen H,Kapesa L,et al.Lauren classification and individualized chemotherapy in gastric cancer[J].Oncol Lett,2016,11:2959- 2964.
• [6] Hu B,El Hajj N,Sittler S,et al.Gastric cancer:classification,histology and application of molecular pathology[J].J Gastrointest Oncol,2012,3:251- 261.
• [7] Crew KD,Neugut AI.Epidemiology of gastric cancer[J].World J Gastroenterol,2006,12:354- 362.
• [8] Amin MB,Edge SB,Greene FL,et al.AJCC Cancer Staging Manual[M].8th ed.New York:Springer,2017.
• [9] Sarela AI,Lefkowitz R,Brennan MF,et al.Selection of patients with gastric adenocarcinoma for laparoscopic staging[J].Am J Surg,2006,191:134- 138.
• [10] Abdalla EK,Pisters PWT.Staging and preoperative evaluation of upper gastrointestinal malignancies[J].Semin Oncol,2004,31:513- 529.
• [11] Mezhir JJ,Shah MA,Jacks LM,et al.Positive peritoneal cytology in patients with gastric cancer:natural history and outcome of 291 patients[J].Ann Surg Oncol,2010,17:3173- 3180.
• [12] Song L,Qian X,Xin D,et al.Efficacy and toxicity of neoadjuvant immune checkpoint inhibitors in resectable gastric cancer:A meta-analysis and systematic review[EB/OL].[2022- 05- 01].https://meetings.asco.org/abstracts-presentations/204818.
• [13] Andre T,Tougeron D,Piessen G,et al.Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA):The GERCOR NEONIPIGA phase Ⅱ study[EB/OL].[2022- 05- 01].https://meetings.asco.org/abstracts-presentations/205214.
• [14] Trabucco SE,Gowen K,Maund SL,et al.A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples[J].J Mol Diagn,2019,21:1053- 1066.
• [15] Willis J,Lefterova MI,Artyomenko A,et al.Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel[J].Clin Cancer Res,2019,25:7035- 7045.
• [16] Kato S,Okamura R,Baumgartner JM,et al.Analysis of circulating tumor DNA and clinical correlates in patients with esophageal,gastroesophageal junction,and gastric adenocarcinoma[J].Clin Cancer Res,2018,24:6248- 6256.
• [17] Dikken JL,Jansen EP,Cats A,et al.Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastic cancer[J].J Clin Oncol,2010,28:2430- 2436.
• [18] Park SH,Sohn TS,Lee J,et al.Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrence chemoradiotherapy in gastric cancer:final report of the Adjuvant Chemoradiotherapy In Stomach Tumors trial,including survival and subset analyses[J].J Clin Oncol,2015,33:3130- 3136.
• [19] Lee J,Lim do H,Kim S,et al.Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:the ARTIST trial[J].J Clin Oncol,2012,30:268- 273.
• [20] Park SH,Lim DH,Sohn TS,et al.A randomized phase Ⅲ trial comparing adjuvant single-agent S1,S- 1 with oxaliplatin,and postoperative chemoradiotion with S- 1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection:the ARTIST 2 trial[J].Ann Oncol,2021,32:368- 374.
• [21] Al-Batran SE,Pauligk C,Homann N,et al.The feasi-bility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer:a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)[J].Eur J Cancer,2013,49:835- 842.
• [22] Van Cutsem E,Moiseyenko VM,Tjulandin S,et al.Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group[J].J Clin Oncol,2006,24:4991- 4997.
• [23] Elsaid AA,Elkerm Y.Final results of a randomized phase Ⅲ trial of docetaxel,carboplatin and 5FU versus epiru-bicin,cisplatin and 5FU for locally advanced gastric cancer[J].J Clin Oncol,2005,23:4014.
• [24] Van Cutsem E,Boni C,Tabernero J,et al.Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer:a randomized phase Ⅱstudy[J].Ann Oncol,2015,26:149- 156.
• [25] Shah MA,Janjigian YY,Stoller R,et al.Randomized multicenter phase Ⅱ study of modified docetaxel,cisplatin,and fluorouracil(DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma:a study of the US Gastric Cancer Consortium[J].J Clin Oncol,2015,33:3874- 3879.
• [26] Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemother-apy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376:687- 697.
• [27] Chung HC,Bang YJ,Fuchs CS,et al.First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer:KEYNOTE-811[J].Future Oncol,2021,17:491- 501.
• [28] Janjigian YY,Shitara K,Moehler M,et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction,and oesophageal adenocarcinoma (CheckMate 649):a randomised,open-label,phase 3 trial[J].Lancet,2021,398:27- 40.
• [29] Fuchs CS,Tomasek J,Yong CJ,et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD):an international,randomised,multicentre,placebo-controlled,phase 3 trial[J].Lancet,2014,383:31- 39.
• [30] Wilke H,Muro K,Van Cutsem E,et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):a double-blind,randomised phase 3 trial[J].Lancet Oncol,2014,15:1224- 1235.
• [31] Oaknin A,Tinker AV,Gilbert L,et al.Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer:a nonrandomized phase 1 clinical trial[J].JAMA Oncol,2020,6:1766- 1772.
• [32] Marabelle A,Le DT,Ascierto PA,et al.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer:results from the phase Ⅱ KEYNOTE- 158 study[J].J Clin Oncol,2020,38:1- 10.